Facts and figures
Facts and figures
Statistics measuring our impact on global immunisation
Updated October 2025; next update: October 2026
Headline stats
US$ 54 for US$ 1 spent
A study covering 73 Gavi-supported countries shows that, for every US$ 1 spent on immunisation in the 2021–2030 period, US$ 21 are saved in health care costs, lost wages and lost productivity due to illness and death. When considering the value people place on lives saved by vaccines – which is likely to include the value of costs averted plus the broader societal value of lives saved and people living longer and healthier lives – the return on investment is estimated to be US$ 54 per US$ 1 spent.
Sim S.Y., Watts E., Constenla D., Brenzel L., Patenaude B.N. Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011–30. Health Affairs, 2020
Strategic goals
Our mission – to save lives and protect people’s health by increasing equitable and sustainable use of vaccines – is supported by four strategic goals.
The vaccine goal
Introduce and scale up vaccines
63%
The 57 Gavi-supported countries increased breadth of protection with vaccines in the Gavi portfolio to 63%, up 8 percentage points from 2023.
108
58 Gavi-supported vaccine introductions and preventive campaigns took place in 2024 – in addition to 50 outbreak response vaccination campaigns supported by Gavi.
32 million
>32.6 million girls fully immunised against HPV with Gavi support in 2024 alone – more than the previous ten years combined.
17
17 countries accessed cholera, meningococcal and yellow fever vaccines through Gavi-supported emergency stockpiles a total of 44 times in 2024.
The equity goal
Strengthen health systems to increase equity in immunisation
82%
In 2024, Gavi-supported countries increased DTP3 coverage to 82% (compared to the 85% global average).
72 million
>72 million children were reached with Gavi-supported routine vaccines in 2024 – more than in any year previously
48
48 countries have installed more than 64,000 cold chain equipment (CCE) units procured by UNICEF Supply Division through Gavi’s CCEOP – nearly 2,700 in 2024 alone.
87%
Average coverage of DTP3 in 26 low-income countries supported by Gavi is not yet back to pre-pandemic levels (i.e. 75% in 2019) – while lower middle-income countries exceeded 2019 coverage by 1 pp, reaching 87% in 2024.
The sustainability goal
Improve sustainability of immunisation programmes
US$ 1.9 billion
In the face of fiscal challenges, climate change, conflict and instability, most Gavi-supported countries maintained or increased domestic resources for co-financing of Gavi-supported vaccines in 2024, bringing to US$ 1.9 billion their total contribution since the introduction of the co-financing policy in 2008.
255 million
US$ 255m was contributed by countries towards the co-financing of Gavi-supported vaccines in 2024 – the highest amount yet and a testament to country ownership and the long-term financial sustainability of Gavi-supported vaccines.
55
55 vaccine programmes originally introduced with Gavi funding are self-financed by countries as of 2023, up from 40 in 2018.
100%
100% of countries fully met their 2024 co-financing obligation – except six waivers for humanitarian crises.
The healthy markets goal
Ensure healthy markets for vaccines and related products
20
Through Gavi’s market shaping efforts, the number of manufacturers supplying prequalified Gavi-supported vaccines reached 20 in 2024 (with nearly half based in low- and middle income countries) – compared with 5 in 2001.
10
10 markets for vaccines and immunisation products exhibited acceptable levels of healthy market dynamics in 2024, meeting the target for the year.
12
12 innovative products were within the pipeline of commercial-scale manufacturers in 2024, continuing to exceed the Alliance target of 8 by 2025 well ahead of schedule.
500,000
500,000 mpox vaccine doses secured within a month of the WHO emergency declaration.